Utility of gene tumor expression of VEGF, FOXM1*3 and CD-133 on diagnosis and prognosis of brain gliomas

ObjectiveThis paper seeks to quantify the normalized expression of transcripts FOXM1*3, VEGF, CD133, and MGMT and their relation with the histopathological and molecular diagnosis and with the probability of estimating tumor progression-free survival of gliomas. MethodsA cohort of patients was made up of patients aged over 18 years with a histological and molecular diagnosis of gliomas from the year 2011 to 2018. The patients had a complete tumor resection. Patients with high-grade glioma received adjuvant management (temozolamide and radiotherapy). Clinical and imaging follow-up was carried out periodically to identify the time of progression free survival (PFS). ResultsNinety-one patients (age range, 18-85 years) comprised the study cohort with a predominance of males. The expression of FOXM1*3, VEGF, and CD133 allowed the differentiation of astrocytomas grade II from GBM. ROC curves proved statistically significant in the GBM model (p < 0.05), demonstrating greatest sensitivity with FOXM1*3 (91%), and greatest specificity with VEGF (93%). The age-adjusted Cox multivariate model established that a PFS50% of 25 months corresponds to a median value of 5.3 for VEGF and 0.42 for CD133. ConclusionsThe normalized expression of transcripts FOXM1*3, VEGF, and CD133 allow us to estimate the probability of PFS, especially in gliomas grades II and IV; likewise, their overexpression defines the diagnosis of GBM. AuthorshipO_LISubstantial contributions to conception and design (IAFR, BNR, MARF, GG, IG), acquisition of data (IAFR, BNR, MARF, IFE, LCP, JCM, SOS, JAC, CRA), analysis and interpretation of data (IAFR, BNR, MARF, JCM, SOS, CEN, HMG, IG). C_LIO_LIDrafting the article (IAFR, BNR, MARF, IFE, LCP, SOS, JAC, IG), revising it critically for important intellectual content (IAFR, JCM, CEN, GG, HMG, CRA, IG) C_LIO_LIFinal approval of the version to be published (IAFR, BNR, MARF, IFE, LCP, JCM, SOS, JAC, CEN, GG, HMG, CRA, IG). C_LI